688506 百利天恒
已收盘 03-06 15:00:01
资讯
新帖
简况
百利天恒（688506）披露注射用BL-M11D1获临床试验批准通知书，3月5日股价上涨4.84%
证券之星 · 03-05 17:20
百利天恒（688506）披露注射用BL-M11D1获临床试验批准通知书，3月5日股价上涨4.84%
百利天恒：自研ADC药物注射用BL-M11D1获批临床
财中社 · 03-04 18:46
百利天恒：自研ADC药物注射用BL-M11D1获批临床
百利天恒累计回购54万股 金额1.61亿元
财中社 · 03-03
百利天恒累计回购54万股 金额1.61亿元
百利天恒：2025年归母净亏损10.51亿元 同比盈转亏
每日经济新闻 · 02-27
百利天恒：2025年归母净亏损10.51亿元 同比盈转亏
首度全年盈利的百济神州，与川股百利天恒有一个共同点：都被这些公募基金重仓
金融投资报 · 02-27
首度全年盈利的百济神州，与川股百利天恒有一个共同点：都被这些公募基金重仓
百利天恒双抗ADC达到Ⅲ期临床试验主要终点 为三阴性乳腺癌治疗提供新选项
每日经济新闻 · 02-24
百利天恒双抗ADC达到Ⅲ期临床试验主要终点 为三阴性乳腺癌治疗提供新选项
百利天恒(688506.SH)：iza-bren(EGFR×HER3双抗ADC)用于局部晚期或转移性三阴乳腺癌III期临试期中分析达到主要终点
智通财经 · 02-23
百利天恒(688506.SH)：iza-bren(EGFR×HER3双抗ADC)用于局部晚期或转移性三阴乳腺癌III期临试期中分析达到主要终点
每周股票复盘：百利天恒（688506）董秘离任由张苏娅代行职责
证券之星 · 02-15
每周股票复盘：百利天恒（688506）董秘离任由张苏娅代行职责
成都创新药龙头企业百利天恒，再冲港股IPO
红星资本局 · 02-13
成都创新药龙头企业百利天恒，再冲港股IPO
百利天恒：董秘陈英格辞职 董事张苏娅代行职责
财中社 · 02-13
百利天恒：董秘陈英格辞职 董事张苏娅代行职责
2月10日百利天恒涨6.14%，中欧医疗健康混合A基金重仓该股
证券之星 · 02-10
2月10日百利天恒涨6.14%，中欧医疗健康混合A基金重仓该股
每周股票复盘：百利天恒（688506）拟发不超100亿债务融资工具
证券之星 · 02-08
每周股票复盘：百利天恒（688506）拟发不超100亿债务融资工具
百利天恒回购32万股 金额9985万元
财中社 · 02-03
百利天恒回购32万股 金额9985万元
百利天恒目标价涨幅近376% 金辰股份评级被调低丨券商评级观察
21世纪经济报道 · 02-02
百利天恒目标价涨幅近376% 金辰股份评级被调低丨券商评级观察
医保数据发布再升级；多家药企发布业绩预告
21世纪经济报道 · 02-02
医保数据发布再升级；多家药企发布业绩预告
股市必读：百利天恒（688506）预计2025年全年营业收入25亿元
证券之星 · 02-02
股市必读：百利天恒（688506）预计2025年全年营业收入25亿元
百利天恒：预计2025年净亏损11亿元 同比转亏
每日经济新闻 · 01-30
百利天恒：预计2025年净亏损11亿元 同比转亏
23股获推荐 百利天恒目标价涨幅超300%丨券商评级观察
21世纪经济报道 · 01-27
23股获推荐 百利天恒目标价涨幅超300%丨券商评级观察
百利天恒（688506）披露召开2026年第一次临时股东会通知，1月23日股价下跌0.38%
证券之星 · 01-23
百利天恒（688506）披露召开2026年第一次临时股东会通知，1月23日股价下跌0.38%
广发基金吴兴武旗下广发保健A年报最新持仓，重仓百利天恒
证券之星 · 01-22
广发基金吴兴武旗下广发保健A年报最新持仓，重仓百利天恒
加载更多
公司概况
公司名称：
四川百利天恒药业股份有限公司
所属行业：
医药制造业
上市日期：
2023-01-06
主营业务：
四川百利天恒药业股份有限公司的主营业务是创新生物药业务板块和化药制剂、中成药制剂业务板块。公司的主要产品是丙泊酚乳状注射液、丙泊酚中/长链脂肪乳注射液、吸入用七氟烷、结构脂肪乳注射液、黄芪颗粒、盐酸胍法辛缓释片、葡萄糖电解质泡腾片。
发行价格：
24.70
{"stockData":{"symbol":"688506","market":"SH","secType":"STK","nameCN":"百利天恒","latestPrice":258.5,"timestamp":1772780401000,"preClose":254.87,"halted":0,"volume":1455274,"delay":0,"changeRate":0.0142,"floatShares":401000000,"shares":413000000,"eps":-2.0646,"marketStatus":"已收盘","change":3.63,"latestTime":"03-06 15:00:01","open":255.54,"high":261.99,"low":252.32,"amount":376000000,"amplitude":0.0379,"askPrice":259.4,"askSize":2,"bidPrice":258.5,"bidSize":158,"shortable":0,"etf":0,"ttmEps":-2.0646,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1773019800000},"marketStatusCode":5,"adr":0,"adjPreClose":254.87,"symbolType":"stock_kcb","openAndCloseTimeList":[[1772760600000,1772767800000],[1772773200000,1772780400000]],"highLimit":280.36,"lowLimit":229.38,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":412873817,"isCdr":false,"pbRate":14.88,"roa":"--","roe":"--","epsLYR":9.25,"committee":0.642512,"marketValue":106728000000,"turnoverRate":0.0036,"status":0,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-03-09。","afterMarket":{"amount":0,"volume":0,"close":258.5,"buyVolume":0,"sellVolume":0,"time":1772782437558,"indexStatus":"已收盘 03-06 15:30:00","preClose":254.87},"hkstockBrief":{"symbol":"02615","market":"HK","secType":"STK","nameCN":"百利天恒","latestPrice":0,"timestamp":1772784000000,"preClose":0,"halted":7,"volume":0,"delay":0,"premium":"-100.00"},"floatMarketCap":103659000000},"requestUrl":"/m/hq/s/688506","defaultTab":"news","newsList":[{"id":"2617517185","title":"百利天恒（688506）披露注射用BL-M11D1获临床试验批准通知书，3月5日股价上涨4.84%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617517185","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617517185?lang=zh_cn&edition=full","pubTime":"2026-03-05 17:20","pubTimestamp":1772702439,"startTime":"0","endTime":"0","summary":"截至2026年3月5日收盘，百利天恒报收于254.87元，较前一交易日上涨4.84%，最新总市值为1052.29亿元。四川百利天恒药业股份有限公司于2026年3月5日发布自愿披露公告，称公司近日收到国家药品监督管理局签发的《药物临床试验批准通知书》，同意公司自主研发的创新生物药注射用BL-M11D1开展用于治疗复发或难治性骨髓增生异常综合征的临床试验。目前BL-M11D1在国内进行Ib期临床试验，在美国进行I期临床试验，适应症为复发或难治性急性髓系白血病。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030500027855.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","02615","688506","91194"],"gpt_icon":0},{"id":"2616318725","title":"百利天恒：自研ADC药物注射用BL-M11D1获批临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2616318725","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616318725?lang=zh_cn&edition=full","pubTime":"2026-03-04 18:46","pubTimestamp":1772621169,"startTime":"0","endTime":"0","summary":"3月4日，百利天恒（688506）发布公告，公司自主研发的创新生物药注射用BL-M11D1（CD33-ADC）的药物临床试验获得批准。BL-M11D1是与iza-bren出自同一技术平台、与iza-bren共享同一“连接子+毒素”平台的靶向CD33的ADC药物。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603043661878918.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4080","91194","02615","LU1815336091.USD","BL","BK4023","ADC","LU0757428866.USD","BK0239","688506","BK4231"],"gpt_icon":0},{"id":"2616834626","title":"百利天恒累计回购54万股 金额1.61亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2616834626","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616834626?lang=zh_cn&edition=full","pubTime":"2026-03-03 18:32","pubTimestamp":1772533937,"startTime":"0","endTime":"0","summary":"3月3日，百利天恒（688506）发布公告，截至2026年2月28日，公司累计回购54万股，占总股本的0.13%，回购资金总额为1.61亿元，实际回购价格区间为267.36元/股至345.24元/股。2025年前三季度，百利天恒实现收入20.66亿元，归母净利润-4.95亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603033660497540.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","02615","688506","91194"],"gpt_icon":0},{"id":"2614799835","title":"百利天恒：2025年归母净亏损10.51亿元 同比盈转亏","url":"https://stock-news.laohu8.com/highlight/detail?id=2614799835","media":"每日经济新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614799835?lang=zh_cn&edition=full","pubTime":"2026-02-27 17:19","pubTimestamp":1772183985,"startTime":"0","endTime":"0","summary":"每经AI快讯，2月27日，百利天恒(688506.SH)发布2025年年度业绩快报，营业总收入为25.20亿元，同比减少56.72%；归属于母公司所有者的净利润为-10.51亿元，同比盈转亏。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602273656760446.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602273656760446.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","688506","02615","91194"],"gpt_icon":0},{"id":"2614083875","title":"首度全年盈利的百济神州，与川股百利天恒有一个共同点：都被这些公募基金重仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2614083875","media":"金融投资报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614083875?lang=zh_cn&edition=full","pubTime":"2026-02-27 16:51","pubTimestamp":1772182279,"startTime":"0","endTime":"0","summary":"金融投资报记者贺梦璐“盈利了，但市值却跌破3000亿元。”这或许是百济神州发布2025年度业绩快报后，留给资本市场的最大困惑。金融投资报记者注意到，当投资者将目光转向其股东名单时，一个有意思的巧合开始浮现：那些重仓百济神州的公募基金，同样也对川股百利天恒青睐有加。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602273656715059.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02615","BK1588","BK4139","BK4526","06160","688506","LU0588546209.SGD","BK1583","BK0239","LU1969619763.USD","LU0307460666.USD","BK4588","LU2328871848.SGD","LU1303224171.USD","688235","LU1719994722.HKD","91194","BK4585","BK1161","LU1251922891.USD","BK1500","ONC","LU1770034418.SGD"],"gpt_icon":0},{"id":"2613713953","title":"百利天恒双抗ADC达到Ⅲ期临床试验主要终点 为三阴性乳腺癌治疗提供新选项","url":"https://stock-news.laohu8.com/highlight/detail?id=2613713953","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613713953?lang=zh_cn&edition=full","pubTime":"2026-02-24 19:39","pubTimestamp":1771933190,"startTime":"0","endTime":"0","summary":"2月23日，百利天恒（SH688506，股价289.59元，市值1195.6亿元）宣布其自主研发的全球首创EGFR×HER3双抗ADC药物（抗体偶联药物）iza-bren，在针对局部晚期或转移性三阴性乳腺癌（TNBC）的Ⅲ期临床试验中取得突破。期中分析数据显示，该药物显著延长了患者的无进展生存期（PFS）和总生存期（OS），达到双主要终点。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602243652920641.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602243652920641.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","BK4080","BK4231","91194","688506","02615","ADC"],"gpt_icon":0},{"id":"2613820071","title":"百利天恒(688506.SH)：iza-bren(EGFR×HER3双抗ADC)用于局部晚期或转移性三阴乳腺癌III期临试期中分析达到主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2613820071","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613820071?lang=zh_cn&edition=full","pubTime":"2026-02-23 16:56","pubTimestamp":1771836964,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百利天恒 披露公告，关于iza-bren用于局部晚期或转移性三阴乳腺癌III期临床试验的期中分析达到主要终点的事项，该III期临床研究独立数据监查委员会，在预设的期中分析中，建议：“基于现有的分析结果，与监管沟通提前申报，同时继续对受试者进行随访”。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1406323.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["91194","BK0239","BK4231","ADC","BK4134","02615","III","688506","BK4080"],"gpt_icon":0},{"id":"2611014356","title":"每周股票复盘：百利天恒（688506）董秘离任由张苏娅代行职责","url":"https://stock-news.laohu8.com/highlight/detail?id=2611014356","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611014356?lang=zh_cn&edition=full","pubTime":"2026-02-15 01:15","pubTimestamp":1771089314,"startTime":"0","endTime":"0","summary":"截至2026年2月13日收盘，百利天恒报收于287.0元，较上周的281.0元上涨2.14%。本周，百利天恒2月11日盘中最高价报299.75元。本周关注点公司公告汇总：董事会秘书陈英格因个人原因离任，由张苏娅代行职责公司公告汇总四川百利天恒药业股份有限公司董事会于2026年2月13日收到董事会秘书陈英格女士的辞呈，因其个人原因申请辞去董事会秘书职务，离任后不再担任公司任何职务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021500000152.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["91194","02615","688506","BK0239"],"gpt_icon":0},{"id":"2611158108","title":"成都创新药龙头企业百利天恒，再冲港股IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2611158108","media":"红星资本局","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611158108?lang=zh_cn&edition=full","pubTime":"2026-02-13 18:08","pubTimestamp":1770977306,"startTime":"0","endTime":"0","summary":"2月10日，成都创新药龙头百利天恒（688506.SH）公告，公司2026年第一次临时股东会通过《关于延长公司发行H股并上市相关决议有效期的议案》，这意味着公司将继续向港股上市发起冲击。此前在2025年11月12日，百利天恒发布公告称，公司决定全球发售将会延迟，且将不会根据招股章程进行。这意味着其原计划11月17日港股挂牌上市的日程被搁置。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602133650512764.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","91194","BK4585","BK1574","06978","VXUS","BK1161","BK4588","VT","688506","159992","02615"],"gpt_icon":0},{"id":"2611137478","title":"百利天恒：董秘陈英格辞职 董事张苏娅代行职责","url":"https://stock-news.laohu8.com/highlight/detail?id=2611137478","media":"财中社","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611137478?lang=zh_cn&edition=full","pubTime":"2026-02-13 17:23","pubTimestamp":1770974596,"startTime":"0","endTime":"0","summary":"百利天恒（688506）发布公告，董事会秘书陈英格因个人原因申请辞去董事会秘书职务，离任时间为2026年2月13日，辞职后，陈英格不再担任公司任何职务。在陈英格离任后，公司董事、高级管理人员张苏娅将代行董事会秘书职责。2025年前三季度，百利天恒实现收入20.66亿元，归母净利润-4.95亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602133650466684.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["688506","BK0239","91194","02615"],"gpt_icon":0},{"id":"2610612060","title":"2月10日百利天恒涨6.14%，中欧医疗健康混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2610612060","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610612060?lang=zh_cn&edition=full","pubTime":"2026-02-10 16:33","pubTimestamp":1770712390,"startTime":"0","endTime":"0","summary":"证券之星消息，2月10日百利天恒涨6.14%，收盘报288.0元，换手率0.85%，成交量3.42万手，成交额9.72亿元。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共131家，其中持有数量最多的公募基金为中欧基金的中欧医疗健康混合A。中欧医疗健康混合A目前规模为138.43亿元，最新净值1.7986，较上一交易日上涨0.17%，近一年上涨16.05%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021000026074.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["91194","BK0239","159760","02615","688506"],"gpt_icon":0},{"id":"2609152376","title":"每周股票复盘：百利天恒（688506）拟发不超100亿债务融资工具","url":"https://stock-news.laohu8.com/highlight/detail?id=2609152376","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609152376?lang=zh_cn&edition=full","pubTime":"2026-02-08 01:33","pubTimestamp":1770485590,"startTime":"0","endTime":"0","summary":"截至2026年2月6日收盘，百利天恒报收于281.0元，较上周的277.75元上涨1.17%。本周，百利天恒2月5日盘中最高价报287.69元。本周关注点公司公告汇总：拟申请注册发行规模不超过人民币100亿元的债务融资工具。四川百利天恒药业股份有限公司于2025年12月30日召开董事会，审议通过以集中竞价交易方式回购公司股份的方案，回购期限为2025年12月30日至2026年12月29日，拟回购金额为10,000万元至20,000万元，回购价格不超过546元/股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020800000287.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688506","02615","91194"],"gpt_icon":0},{"id":"2608822501","title":"百利天恒回购32万股 金额9985万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608822501","media":"财中社","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608822501?lang=zh_cn&edition=full","pubTime":"2026-02-03 18:17","pubTimestamp":1770113866,"startTime":"0","endTime":"0","summary":"2月3日，百利天恒（688506）发布公告，截至2026年1月31日，公司已回购32万股，占总股本的0.08%，回购资金总额为9985万元，回购价格区间为279.72元/股至345.24元/股。2025年前三季度，百利天恒实现收入20.66亿元，归母净利润-4.95亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602033640244377.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["91194","02615","BK0239","688506"],"gpt_icon":0},{"id":"2608838285","title":"百利天恒目标价涨幅近376% 金辰股份评级被调低丨券商评级观察","url":"https://stock-news.laohu8.com/highlight/detail?id=2608838285","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608838285?lang=zh_cn&edition=full","pubTime":"2026-02-02 09:19","pubTimestamp":1769995154,"startTime":"0","endTime":"0","summary":"南财投研通数据显示，1月26日至2月1日，券商给予上市公司目标价共103次，按最新收盘价计算，目标价涨幅排名居前的公司有百利天恒、泽璟制药、长城汽车，目标价涨幅分别为375.97%、88.56%、83.66%，前两者分别属于化学制药行业，后者属于乘用车行业。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602023638055674.html","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602023638055674.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02615","91194","603396","688506"],"gpt_icon":0},{"id":"2608887409","title":"医保数据发布再升级；多家药企发布业绩预告","url":"https://stock-news.laohu8.com/highlight/detail?id=2608887409","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608887409?lang=zh_cn&edition=full","pubTime":"2026-02-02 08:04","pubTimestamp":1769990666,"startTime":"0","endTime":"0","summary":"政策动向医保数据发布再升级2月1日，国家医保局官微发文称，医保数据工作组是医保部门的一项创新性工作。数据发布活动组织一年多以来，各地发布内容不断丰富，发布形式更加多样，一些地方基于按病种付费改革开展病种专题分析，为疾病诊疗资源消耗“画像”，为医疗机构提供更加具体、好用的管理工具。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602023638025174.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602023638025174.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","BK0046","BK0239","LU1064131003.USD","LU2148510915.USD","CDE","BK0077","BK1583","LU1223082196.USD","000661","LU1328615791.USD","LU2580892862.HKD","BK0188","LU2328871848.SGD","LU1064130708.USD","BK1161","688506","BK0075","LU1969619763.USD","300122","LU2580892789.USD","BK0196","LU1223083913.SGD","688331","LU1223082519.USD","BK4017","LU2488822045.USD","BK0057","09995","BK0028"],"gpt_icon":0},{"id":"2608886409","title":"股市必读：百利天恒（688506）预计2025年全年营业收入25亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608886409","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608886409?lang=zh_cn&edition=full","pubTime":"2026-02-02 02:33","pubTimestamp":1769970791,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，百利天恒报收于277.75元，下跌0.3%，换手率0.42%，成交量1.7万手，成交额4.8亿元。业绩披露要点业绩预告百利天恒发布业绩预告，预计2025年全年归属净利润亏损约11亿元；扣非后净利润亏损约12亿元；营业收入预计为25亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020200001204.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02615","688506","91194"],"gpt_icon":0},{"id":"2607432016","title":"百利天恒：预计2025年净亏损11亿元 同比转亏","url":"https://stock-news.laohu8.com/highlight/detail?id=2607432016","media":"每日经济新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607432016?lang=zh_cn&edition=full","pubTime":"2026-01-30 18:02","pubTimestamp":1769767349,"startTime":"0","endTime":"0","summary":"每经AI快讯，1月30日，百利天恒(688506.SH)公告称，预计2025年度归属于上市公司股东的净利润为-11.00亿元左右，上年同期为盈利37.08亿元，同比转亏。报告期内，公司持续加大研发投入，导致研发投入同比增幅较大。截至报告期末，公司共有17款创新药处于临床试验阶段（其中6款创新药处于全球临床试验）。公司正在全球范围内开展100余项创新药临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601303637105727.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601303637105727.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["688506","BK0239","91194","02615"],"gpt_icon":0},{"id":"2606176278","title":"23股获推荐 百利天恒目标价涨幅超300%丨券商评级观察","url":"https://stock-news.laohu8.com/highlight/detail?id=2606176278","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606176278?lang=zh_cn&edition=full","pubTime":"2026-01-27 09:09","pubTimestamp":1769476169,"startTime":"0","endTime":"0","summary":"南财投研通数据显示，1月26日，券商给予上市公司目标价共9次，按最新收盘价计算，目标价涨幅排名居前的公司有百利天恒、洛阳钼业、三七互娱，目标价涨幅分别为368.30%、37.88%、29.53%，分别属于化学制药、工业金属、游戏行业。从券商推荐家数来看，1月26日有23家上市公司得到券商推荐，其中建发股份、首华燃气、花园生物等获得1家推荐。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601273631460230.html","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601273631460230.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["688506","02615","91194"],"gpt_icon":0},{"id":"2605054604","title":"百利天恒（688506）披露召开2026年第一次临时股东会通知，1月23日股价下跌0.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2605054604","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605054604?lang=zh_cn&edition=full","pubTime":"2026-01-23 22:20","pubTimestamp":1769178004,"startTime":"0","endTime":"0","summary":"截至2026年1月23日收盘，百利天恒报收于290.61元，较前一交易日下跌0.38%，最新总市值为1199.85亿元。该股当日开盘291.75元，最高294.99元，最低285.33元，成交额达5.94亿元，换手率为0.51%。近日，四川百利天恒药业股份有限公司发布《关于召开2026年第一次临时股东会的通知》。公告显示，公司定于2026年2月9日召开2026年第一次临时股东会，会议采取现场投票与网络投票相结合方式。股权登记日为2026年2月2日。股东可委托代理人出席。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012300043025.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688506","02615","BK0239","91194"],"gpt_icon":0},{"id":"2605593460","title":"广发基金吴兴武旗下广发保健A年报最新持仓，重仓百利天恒","url":"https://stock-news.laohu8.com/highlight/detail?id=2605593460","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605593460?lang=zh_cn&edition=full","pubTime":"2026-01-22 18:58","pubTimestamp":1769079533,"startTime":"0","endTime":"0","summary":"证券之星消息，1月22日广发基金旗下吴兴武管理的广发医疗保健股票型基金公布年报，近1年净值增长率16.73%。与上一季度相比，该基金前十大重仓股新增海思科，三生国健，信立泰；其中百利天恒持仓占比7.26%，为该基金第一大重仓股；新诺威，百济神州，一品红等退出前十大重仓股；详细数据如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012200033876.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688506","91194","02615","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1772859107401,"stockEarnings":[{"period":"1week","weight":-0.0231},{"period":"1month","weight":-0.0598},{"period":"3month","weight":-0.2897},{"period":"6month","weight":-0.3338},{"period":"1year","weight":0.1871},{"period":"ytd","weight":-0.1999}],"compareEarnings":[{"period":"1week","weight":-0.0093},{"period":"1month","weight":0.0054},{"period":"3month","weight":0.0567},{"period":"6month","weight":0.0818},{"period":"1year","weight":0.2198},{"period":"ytd","weight":0.0391}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"四川百利天恒药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"5979人(较上一季度增加25.08%)","perCapita":"67068股","listingDate":"2023-01-06","address":"四川省成都市温江区成都海峡两岸科技产业园百利路161号一幢一号","registeredCapital":"41287万元","survey":" 四川百利天恒药业股份有限公司的主营业务是创新生物药业务板块和化药制剂、中成药制剂业务板块。公司的主要产品是丙泊酚乳状注射液、丙泊酚中/长链脂肪乳注射液、吸入用七氟烷、结构脂肪乳注射液、黄芪颗粒、盐酸胍法辛缓释片、葡萄糖电解质泡腾片。","listedPrice":24.7},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百利天恒(688506)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百利天恒(688506)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百利天恒,688506,百利天恒股票,百利天恒股票老虎,百利天恒股票老虎国际,百利天恒行情,百利天恒股票行情,百利天恒股价,百利天恒股市,百利天恒股票价格,百利天恒股票交易,百利天恒股票购买,百利天恒股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百利天恒(688506)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百利天恒(688506)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}